{rfName}
Sc

Indexed in

License and use

Icono OpenAccess

Citations

7

Altmetrics

Analysis of institutional authors

Pintado-Berninches LAuthor

Share

November 20, 2023
Publications
>
Article
Sí

Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2

Publicated to:Cell Death & Disease. 14 (11): 742- - 2023-11-01 14(11), DOI: 10.1038/s41419-023-06255-4

Authors: Bartolomé, RA; Martín-Regalado, A; Pintado-Berninches, L; Robles, J; Ramírez-González, MA; Boukich, I; Sanchez-Gómez, P; Balyasnikova, IV; Casal, JI

Affiliations

CSIC - Centro de Investigaciones Biológicas Margarita Salas (CIB) - Author
CSIC - Centro de Investigaciones Biológicas Margarita Salas (CIB) , Protein Alternatives SL - Author
Ctr Invest Biol CIB CSIC, Dept Mol Biomed, Ramiro de Maeztu 9, Madrid 28040, Spain - Author
Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron, Madrid, Spain - Author
Northwestern Univ, Dept Neurol Surg, Chicago, IL USA - Author
Northwestern Univ, Northwestern Med Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA - Author
Northwestern University Feinberg School of Medicine , Northwestern University - Author
Prot Alternat SL, Tres Cantos, Madrid, Spain - Author
Unidad Funcional de Investigación de Enfermedades Crónicas - Author
Univ Autonoma Madrid, Madrid, Spain - Author
Universidad Autónoma de Madrid , CSIC - Centro de Investigaciones Biológicas Margarita Salas (CIB) - Author
See more

Abstract

Interleukin 13 receptor alpha 2 (IL13Rα2) is a relevant therapeutic target in glioblastoma (GBM) and other tumors associated with tumor growth and invasion. In a previous study, we demonstrated that protein tyrosine phosphatase 1B (PTP1B) is a key mediator of the IL-13/IL13Rα2 signaling pathway. PTP1B regulates cancer cell invasion through Src activation. However, PTP1B/Src downstream signaling mechanisms that modulate the invasion process remain unclear. In the present research, we have characterized the PTP1B interactome and the PTP1B-associated phosphoproteome after IL-13 treatment, in different cellular contexts, using proteomic strategies. PTP1B was associated with proteins involved in signal transduction, vesicle transport, and with multiple proteins from the NF-κB signaling pathway, including Tenascin-C (TNC). PTP1B participated with NF-κB in TNC-mediated proliferation and invasion. Analysis of the phosphorylation patterns obtained after PTP1B activation with IL-13 showed increased phosphorylation of the transcription factor Schnurri-3 (SHN3), a reported competitor of NF-κB. SHN3 silencing caused a potent inhibition in cell invasion and proliferation, associated with a down-regulation of the Wnt/β-catenin pathway, an extensive decline of MMP9 expression and the subsequent inhibition of tumor growth and metastasis in mouse models. Regarding clinical value, high expression of SHN3 was associated with poor survival in GBM, showing a significant correlation with the classical and mesenchymal subtypes. In CRC, SHN3 expression showed a preferential association with the mesenchymal subtypes CMS4 and CRIS-B. Moreover, SHN3 expression strongly correlated with IL13Rα2 and MMP9-associated poor prognosis in different cancers. In conclusion, we have uncovered the participation of SNH3 in the IL-13/IL13Rα2/PTP1B pathway to promote tumor growth and invasion. These findings support a potential therapeutic value for SHN3.

Keywords

colorectal-cancergene-expressionglioblastomainhibitionmetastasisnf-kappa-bpoor-prognosisproteinptp1bTyrosine-phosphatase 1b

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cell Death & Disease due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 33/205, thus managing to position itself as a Q1 (Primer Cuartil), in the category Cell Biology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.57, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-17, the following number of citations:

  • Scopus: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-17:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 6.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 6 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.25.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.